Introduction
============

Acute heart failure (AHF) episodes that induce hospitalizations represent one of the largest causes of health status deterioration \[[@ref1]\]. About 45% of patients hospitalized with AHF will be rehospitalized at least once (and 15% at least twice) within 12 months \[[@ref2]\]. Estimates of the risk of death or rehospitalization within 60 days of admission vary from 30% to 60%, depending on the population studied \[[@ref2]-[@ref8]\]. A significant proportion of heart failure (HF) patients do not undertake any device implant strategy since they do not meet the guidelines criteria \[[@ref2]\]. Very little, if any, monitored information exists in those patients experiencing AHF with modest left ventricle impairment or with HF with preserved left ventricular ejection fraction (LVEF). Timely information might allow interventions that then avoid major cardiovascular (CV) events and possible progressive worsening of the disease leading to hospitalization. The availability of implantable devices to continuously monitor cardiac trends may provide early warning of changes in cardiac status, which would then allow early clinical management and possibly reduce the number of HF hospitalizations. The CARdiac RhYthm monitorING after acute decompensatiON for Heart Failure (CARRYING ON for HF) trial was designed to assess the efficacy of implantable loop recorders (ILRs) in the early detection of prespecified clinical and arrhythmic events in this patient population.

Methods
=======

Study Design and Patient Population
-----------------------------------

In this prospective pilot study, patients who were hospitalized for AHF, had an LVEF \<40% but no immediate indication for device implant, and received an ILR before hospital discharge were enrolled.

Clinical follow-up visits were scheduled at 3 and 6 months and every 6 months thereafter. Device data were reviewed monthly through the Care-Link remote monitoring system or at any time the patients had symptoms (ClinicalTrials.gov; Identifier: NCT01216670). CARRYING-ON for HF Study design is reported in [Figure 1](#figure1){ref-type="fig"}.

Informed consent was obtained from each enrolled patient and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the local ethics committee.

The aim of the study was to assess the capability of loop recording to recognize early signs of prespecified clinical and arrhythmic events in this cohort of patients. Prespecified events were: (1) CV mortality or unplanned CV hospitalization and (2) any cardiac arrhythmic event detected by the implanted device (Sinus bradycardia: ≤ 30 beats per minutes (bpm), ≥ 8s; Sinus arrest: ≥ 5s; atrioventricular (AV) block (2°, 3°): ≤ 30 bpm, ≥ 8s; atrial fibrillation (AF): \> 6 min; non-sustained ventricular tachycardia (VT): ≥ 125 bpm, ≥16 beats; sustained VT: \> 30 sec). The main inclusion criteria were: (1) a history of at least 1 HF hospitalization, emergency department visit, or urgent office visit necessitating intravenous (IV) diuretic or augmentation of oral diuretic, IV inotropic, or IV vasodilator or other HF parenteral therapy within 15 days prior to device implant; (2) an implanted Medtronic Reveal XT ILR device (\< 15 days post-implant); and (3) LVEF \< 40%. Main exclusion criteria were: (1) New York Heart Association (NYHA) Class IV (chronic or ambulatory); (2) planned or previous implant of an implantable cardioverter defibrillator (ICD) or pacemaker device; (3) severe chronic obstructive pulmonary disease; (4) permanent AF at time of enrolment; and (5) ST segment elevation at electrocardiogram (ECG). A Reveal XT ILR was used for continuous cardiac monitoring. The ILR was implanted within 15 days the AHF event. All the patients enrolled received a remote monitoring system and were requested to transmit Reveal XT data on a monthly base or in case any symptoms occurred.

![Study design.](resprot_v5i2e62_fig1){#figure1}

Statistical Analysis
--------------------

Continuous data were summarized as mean and standard deviation or median and 25th-75th percentiles in case of skewed distributions. Absolute and relative frequencies were reported for categorical variables. Kaplan-Meier method was used to display the time to first event. The mean cumulative function (MCF) plot for the number of recurrent events was used to display the overtime trend of the events rate. Statistical analyses were performed using SAS 9.3 for Windows (SAS Institute Inc, Cary, NC).

Results
=======

Baseline Characteristics
------------------------

The patients on average were 73±10 years old, 12 (67%) were male, and 7 (39%) had ischemic cardiomyopathy. According to guidelines, all the patients at the time of enrollment had no immediate indication to receive a permanent implantable cardiac device: 8 (44%) patients had LVEF \> 35%, 2patients were in NYHA functional class I, and 9 (50%) patients were not under optimized pharmacological treatment for HF at the time of the AHF event. Most patients (15/18, 83%) were on beta-blocker therapy (11 were on bisoprolol 2.5 mg twice a day and 4 were on carvedilol 12.5 mg twice a day). Further baseline characteristics are reported in [Table 1](#table1){ref-type="table"}.

###### 

Baseline characteristics of study population.

  -------------------------------------------------------------------------------------
  Baseline Patients Characteristics^a^   \                                   N=18 (%)
  -------------------------------------- ----------------------------------- ----------
  Age, y                                 \                                   73±10

  Gender                                 Male                                12 (67%)

  Ischemic etiology                      \                                   7 (39%)

  History of AF                          \                                   8 (44%)

  CHADS~2~ score (for AF patients)       \                                   3.0+0.7

  History of NS-VT                       \                                   2 (18%)

  QRS complex, ms                        \                                   106±23

  LBBB                                   \                                   4 (22%)

  \                                      \                                   \

  NYHA                                   Functional class I                  2 (11%)

  \                                      Functional class II                 13 (72%)

  \                                      Functional class III                3 (17%)

  \                                      \                                   \

  Cardiovascular-Related Diseases        MI + CAD                            6 (35%)

  \                                      Hypertension                        11 (65%)

  \                                      Valvular heart disease              6 (35%)

  \                                      Previous cardiovascular surgeries   9 (50%)

  \                                      Type 2 diabetes                     4 (22%)

  \                                      \                                   \

  \                                      \                                   \

  Echocardiographic Measurements         LVEF (%)                            34±6.0

  \                                      LVEF ≤ 35%                          10 (56%)

  \                                      LVESV, mL                           108±38

  \                                      LVESV ≥ 100 mL                      7 (47%)

  \                                      \                                   \

  Drug Therapy at Discharge              Diuretic                            17 (94%)

  \                                      ACE inhibitor and/or ARB            16 (89%)

  \                                      Beta blocker                        15 (83%)

  \                                      Amiodarone                          10 (56%)

  \                                      Anticoagulant                       14 (78%)
  -------------------------------------------------------------------------------------

Abbreviations: ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CAD, coronary artery disease; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MI, myocardial infarction; NS-VT, non-sustained ventricular tachycardia; NYHA, New York Heart Association.

^a^Data are expressed as mean ± standard deviation or absolute (relative) frequencies.

Clinical Outcomes
-----------------

During a median follow-up of 593 days (mean 509+260), major CV events occurred in 13 patients (72%, median time to first combined event 162 days (39-606)); 11 patients had at least 1 cardiac arrhythmic event, 2 had at least 1 clinical event (CV hospitalization or CV death), and 4 had both arrhythmic and clinical events. [Figure 2](#figure2){ref-type="fig"} shows clinical and arrhythmic events incidence and distribution.

Six (33%) patients experienced 10 major clinical events; 5 (50%) of which were HF-related with 1 patient dying due to HF (terminal rhythm: asystole) and 1 patient dying due to an acute CV event (ruptured cerebral aneurysm). Distribution of detected major clinical and arrhythmic events is reported in [Table 2](#table2){ref-type="table"}.

###### 

Type and frequency of clinical and arrhythmic events that occurred^a^.

  -----------------------------------------------------------------------------------------------------------------------------
  Clinical Events              \                                                Events (n=10)     Patients with Events (n=6)
  ---------------------------- ------------------------------------------------ ----------------- -----------------------------
  CV death^b^, n (%)           \                                                2 (20%)           2 (33%)

  \                            of which HF-related death, n (%)                 1 (10%)           1 (1.7%)

  CV hospitalizations, n (%)   \                                                10 (100%)         6 (100%)

  \                            of which HF-related hospitalizations, n (%)      5 (50%)           3 (50%)

  \                            \                                                \                 \

  Arrhythmic Events            \                                                Events (n=1326)   Patients with Events (n=11)

  \                            Synus bradycardia, n (%) (≤ 30 bpm, ≥ 8s)        8 (0.6%)          3 (27%)

  \                            Sinus arrest, n (%) (≥ 5s)                       2 (0.2%)          2 (18%)

  \                            AV block, n (%) (≤ 30 bpm, ≥ 8s)                 \--               \--

  \                            AF-AT, n (%) (\> 6 min)                          1297 (97.7%)      8 (73%)

  \                            Non-Sustained VT, n (%) (≥ 125 bpm, ≥16 beats)   13 (1%)           2 (18%)

  \                            Sustained VT, n (%) (\> 30 sec)                  6 (0.5%)          2 (18%)
  -----------------------------------------------------------------------------------------------------------------------------

Abbreviations: AF, atrial fibrillation; AT, atrial tachycardia; AV, atrioventricular; CV, cardiovascular; HF, heart failure; VT, ventricular tachycardia.

^a^Data are expressed as absolute (relative) frequencies.

^b^The 2 events of death also had previous hospitalizations.

During follow-up, 3 (16%) patients were implanted with a permanent cardiac device according to current guidelines (in 2 patients who developed sustained-VT, a cardiac resynchronization therapy with defibrillator backup device (CRT-D) was implanted; in the 1 patient with sinus arrest and LVEF \< 35%, a single chamber ICD was implanted). Eight patients suffered paroxysmal AF that was often asymptomatic (62%); the mean CHADS~2~ score in these 8 patients was 3.0+0.7, as all had a CHADS~2~ score ≥2.

As per heart rate (HR), we computed its circadian behavior: the 2 patients who had a nocturnal HR \> 70 bpm for \> 85% of the night had major clinical events, while this occurred in only 3/16 (19%) of the patients with nocturnal HR \< 70 bmp.

[Figure 3](#figure3){ref-type="fig"} shows Kaplan-Meier analysis for clinical and arrhythmic events, both for time to first combined event ([Figure 3](#figure3){ref-type="fig"}a) and for cumulative combined events incidence ([Figure 3](#figure3){ref-type="fig"}b).

![Clinical and arrhythmic events incidence and distribution.](resprot_v5i2e62_fig2){#figure2}

![Kaplan-meier analysis for clinical and arrhythmic events.](resprot_v5i2e62_fig3){#figure3}

Discussion
==========

The main finding from this study, which might carry significant clinical implications, is that continuous ECG and HR monitoring by loop recorders might contribute to the early recognition of cardiac rhythm abnormalities contributing to an observed very high incidence of major CV (72%) events. Such high event risk is known to occur in patients with LVEF \< 40% who are not eligible for ICD implant within 6 months after an HF hospitalization. The study population, despite its small size, was representative of the clinical reality: elderly patients, prevalently NYHA class II, with a mean CHADS~2~ score of 3. The high morbidity detected in the study was not unexpected, but the clinical information provided by the CARRYING ON for HF study deserves specific attention. We can conjecture that the appropriate use of remote monitoring as part of a more comprehensive approach to such patients may decrease the observed high re-hospitalization rate after an AHF. The CARRYING-ON HF study was designed to record events but did not prescribe any specific intervention. It is, however, reasonable to believe that the early detection of rhythm and conduction disturbances by ILR will allow clinicians to react appropriately in a more timely manner, avoiding quick progression of the disease and worst outcomes.

In fact, half of the study population had an AHF during the study period. These patients were being treated with a suboptimal HF medical strategy and the continuous monitoring led to subsequent optimal medical titration for HF, arrhythmia management, and stroke prevention. This should be understood in view of the CRYSTAL AF study \[[@ref9]\] indicating that stroke may be the first clinical manifestation of AF. The analysis of the time to first combined event ([Figure 3](#figure3){ref-type="fig"}) and of the cumulative combined events provides further important information. The first is that a 6-month-long monitoring period is not sufficient to detect a first significant event in all the patients who are bound to have them. Secondly, beyond 6 months a small proportion of combined events occurred possibly because of the fatal event on one side and the optimization of patient management induced by the monitoring device on the other. In this context it is noteworthy that 16/18 (89%) patients had an optimal nocturnal HR (less \< 70 bpm). Thus, it may not be incidental that the only 2 patients with an overnight inappropriate HR had clinical events while this occurred in only 3/16 (19%) patients with controlled nocturnal HR. This observation is indeed coherent with the predictive value of HR and its circadian variation \[[@ref10]-[@ref11]\]. Furthermore the ILR detected episodes of sustained VT that met the criteria for 2 CRT-D implants. In a third case, a detection of a life-threatening event occurred: nocturnal long pauses (\> 8 sec) were discovered. In this patient, the concomitant presence of LVEF \< 35% and the AV conduction disturbance led to a single chamber ICD implant. These 3 cases were diagnosed by the ILR and allowed the timely intervention that prevented a potential life-threatening event.

Limitations
-----------

The main limitation of this pilot study is the small number of patients enrolled. Our study, planned as a feasibility and methodology study, was not powered to determine the overall prevalence of CV events after an AHF episode nor to test the effectiveness of ILR in reducing CV events in this population. The primary aim was descriptive as a preliminary fundamental information to design a larger comparative study.

Conclusions
-----------

The CARRYING ON for HF study provided meaningful information on the many (72%) patients hospitalized for an acute HF episode who are not eligible, according to current guidelines, to receive an implantable cardiac device and who later develop CV and arrhythmic events during the follow-up.

The present finding provides some background for future prospective studies aimed at the assessment of the risk stratification of continuous cardiac monitoring in HF patients who are not deemed eligible for immediate implantation of a permanent cardiac device.
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